Propranolol in Angiosarcoma (NCT04518124) | Clinical Trial Compass
CompletedPhase 2
Propranolol in Angiosarcoma
Netherlands14 participantsStarted 2019-12-27
Plain-language summary
This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate both the clinical response and histological response, without a significant delay in anti-cancer treatment.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Histological proof of angiosarcoma
✓. Patients with primary, recurrent and metastasised disease are eligible;
✓. Patients with a window of at least 3 weeks before surgery or systemic therapy;
✓. Age ≥ 18 years;
✓. Able and willing to give written informed consent;
✓. WHO performance status of 0, 1 or 2;
✓. Evaluable disease according to RECIST 1.1 criteria; radiologic visible disease is not obligated in patients with cutaneous angiosarcoma
✓. Minimal acceptable safety laboratory values
Exclusion criteria
✕. Contraindication for propranolol therapy, like severe hypotension or bradycardia, sicksinus syndrome, second or third grade heart block, cardiogenic shock, untreated heart failure, severe peripheral vascular disease asthma or other obstructive lung diseases, untreated pheochromocytoma, metabolic acidosis, prolonged fasting.
✕. Current treatment with β-blockade therapy.
✕. Any anticancer treatment within 30 days prior to receiving the first dose of investigational treatment; with the exception of hormonal therapy for breast cancer.
✕. Concurrent treatment with an anticancer therapy: with the exception of hormonal therapy for breast cancer.
What they're measuring
1
Clinical response
Timeframe: From start to end of treatment: 3-6 weeks
✕. Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance;
✕. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications;